Novo Nordisk's Oral Weight-Loss Pill Approved, Targeting $150 Billion Market
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Newsfilter
- Drug Approval: Novo Nordisk's 25 mg oral semaglutide weight-loss pill received FDA approval, which is expected to significantly enhance its competitive position in the weight-loss market, particularly against Eli Lilly.
- Weight Loss Efficacy: Clinical trials demonstrated that participants taking the drug lost an average of 16.6% of their body weight compared to just 2.7% for the placebo group, which will likely attract more patients seeking effective weight-loss solutions.
- Massive Market Potential: The approval opens the door for Novo Nordisk to tap into a global weight-loss market projected to reach $150 billion by 2030, potentially reaching tens of millions of patients.
- Increased Production Capacity: Novo Nordisk is manufacturing the pill in North Carolina and has built up ample supplies to meet market demand, which is expected to drive a sales recovery in the U.S. market.
LLY
$1076.48+Infinity%1D
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LLY is 1078 USD with a low forecast of 800.00 USD and a high forecast of 1300 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 1071.440
Low
800.00
Averages
1078
High
1300
Current: 1071.440
Low
800.00
Averages
1078
High
1300
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, markets, and sells pharmaceutical products worldwide. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE-102; VERVE-201, and VERVE-301. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company is also engaged in radiopharmaceutical discovery, development, and manufacturing efforts, and clinical and pre-clinical radioligand therapies in development for the treatment of cancer. It is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD). It is evaluating its novel gene therapy candidate, ixoberogene soroparvovec.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
